Meyer Vitabiotics, a subsidiary of the UK’s leading vitamin company Vitabiotics Ltd, has conducted a study showcasing the benefits of antioxidant micronutrients and vitamins in improving male fertility. The study revealed a 76% improvement in male fertility parameters, even in severe cases of infertility, among 300 Indian males suffering from various types and degrees of infertility.
Infertility is a significant concern worldwide, with male infertility accounting for 20-30% of total cases. Existing treatment options, such as surgery, hormonal therapy, and drug therapy, are often costly, uncertain in their effectiveness, and come with potential side effects. The trial aimed to study the efficacy of an antioxidant blend in sub-fertile males, focusing on improving semen parameters and the DNA Fragmentation Index (DFI).
The encouraging results of the study highlight the potential of multi-micronutrient therapy as a convenient, cost-effective, and clinically proven alternative to current treatment options. Antioxidant therapy has gained traction among clinicians and researchers as a potential solution to male infertility issues. The Oligocare Forte Plus tablet, also known as Wellman Conception in the UK, combines essential micronutrients, amino acids, antioxidants, and vitamins crucial for male reproductive health.
Common causes of male infertility include Oligospermia, Asthenozoospermia, and Teratozoospermia, abnormalities in semen parameters. Frequently prescribed antioxidants for treating male infertility include vitamins E and C, carnitine, N-acetyl cysteine, selenium, and zinc.
The uniqueness of Meyer Vitabiotics’ trial lies in the inclusion of DFI as an assessment factor before and after treatment, offering a new perspective on male infertility treatment. The promising results provide hope for a more accessible, cost-effective, and clinically efficient approach to addressing male infertility through antioxidant and micronutrient therapy.
Author
-
Similar Posts
Pharmaceuticals Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia
Pharmaceuticals Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Switzerland
Pharmaceuticals New Mood Support Patent for Affron® Saffron
